12 The 2010 McDonald Criteria for Diagnosis Clinical presentation 1 attack; objective clinical evidence of 2 lesions Additional data needed Simultaneous presence of asymptomatic gadolinium-enhancing and non enhancing lesions at any time: or A new T2 and/or gadolinium-enhancing lesion(s) on follow-up MRI, irrespective of its timing with reference to a baseline scan; or Await a second clinical attack

13 The 2010 McDonald Criteria for Diagnosis Clinical presentation 1 attack; objective clinical evidence of 1 lesion (clinically isolated syndrome) Additional data needed For DIS: 1 T2 lesion in at least 2 of 4 MS-typical regions of the CNS; or Await a second clinical attack implicating a different CNS site: and For DIT: Simultaneous presence of asymptomatic gadoliniumenhancing and nonenhancing lesions at any time; or A new T2 and/or gadoliniumenhancing lesion(s) on followup MRI irrespective of its timing with reference to a baseline scan; or Await a second clinical attack

14 The 2010 McDonald Criteria for Diagnosis Clinical presentation Insidious neurological progression suggestive of MS Additional data needed One year of disease progression (retrospectively or prospectively determined) plus 2 of 3 of the following criteriad: 1. Evidence for DIS in the brain based on 1 T2 lesions in the MS characteristic (periventricular, juxtacortical, or infratentorial) region 2. Evidence for DIS in the spinal cord based on 2 T2 lesions in the cord 3. Positive CSF (isoelectric focusing evidence of oligoclonal bands and/or elevated IgG index)

15 Refractory MS the occurrence of three or more relapses in a 12-month period, significant increase in MRI lesions, or progression of disability in spite of immunomodulatory therapy.

21 Conclusion Treatment pediatric MS is based on randomized controlled data in adults. No randomized controlled trials in children. It s very difficulty to prevent relapses of MS in our hospital because of no drugs (IFN-beta, glatiramer acetate). We have only cyclophosphamide.(?)

AVONEX/BETASERON/COPAXONE/EXTAVIA/GILENYA/REBIF/TYSABRI Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 5 PATIENT INFMATION Surname First Name Middle Initial Sex Date

The Nuts and Bolts of Multiple Sclerosis Rebecca Milholland, M.D., Ph.D. Center for Neurosciences Objectives Discuss which patients are at risk for Multiple Sclerosis Discuss the diagnostic criteria for

CNS DEMYLINATING DISORDERS Multiple sclerosis A Dutch saint named Lidwina, who died in 1433, may have been one of the first known MS patients. After she fell while ice skating, she developed symptoms such

FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to

ABN Guidelines for 2007 Treatment of Multiple Sclerosis with ß-interferon and Glatiramer Acetate Published by the Association of British Neurologists Ormond House, 27 Boswell Street, London WC1N 3JZ Contents

Disease Modifying Therapies for MS The term disease-modifying therapy means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks

Disease Modifying Therapies for MS The term disease-modifying therapy (DMT) means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks

Which injectable medication should I take for relapsing-remitting multiple sclerosis? A decision aid to discuss options with your doctor This decision aid is for you if you: Have multiple sclerosis Have

What is MS? 1 Neuron Damaged myelin due to inflammation MS is a chronic immunemediated disease that affects the central nervous system (CNS) Is a disease that affects both white and gray matter Interrupted

Resources for the Primary Care Provider Please print these out for reference Resources for providers American Academy of Neurology www.aan.com Provides education and resources, such as guidelines for clinical

Choices Disease Modifying Treatments Disease modifying treatments (DMTs) are medications which modify the disease course. They target inflammation and are designed to reduce the damage caused by relapses.

Revised (2009) guidelines for prescribing in multiple sclerosis INTRODUCTION In January 2001, the (ABN) first published guidelines for the use of licensed disease modifying treatments (ß-interferon and

Oxford University Hospitals NHS Trust Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis Information for patients page 2 What is Natalizumab and what is it used for? Natalizumab is an

DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS* Benjamin M. Greenberg, MD, MHS ABSTRACT Four major disease-modifying therapies are discussed within the context of relapsing and remitting

Specialist Working Group for Neurology Proposed changes to the Criteria for the clinical use of intravenous immunoglobulin in Australia, Second Edition ITEM Condition Name Multiple Sclerosis (MS) Multiple

OHTAC Recommendation Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency Presented to the Ontario Health Technology Advisory Committee in May 2010 May 2010 Issue Background A review on the

III./5.3.: Multiple sclerosis Epidemiology Multiple sclerosis (MS) is the most common neuroimmunological disorder of the central nervous system. This chronic illness begins in early adulthood, mostly at

Conflict of Interest Declaration Overview of New Medications for Multiple Sclerosis I or my spouse have no actual or potential conflict of interest in relation to this activity. Crystal Obering, Pharm.D.,

Cost-effectiveness of teriflunomide (Aubagio ) for the treatment of adult patients with relapsing remitting multiple sclerosis The NCPE has issued a recommendation regarding the cost-effectiveness of teriflunomide

Progress in the field: therapeutic improvements for all patients? Krzysztof Selmaj, Department of Neurology, Medical University of Lodz, PL Warsaw 15 May, 2015 Main features of MS Inflammation Demyelination

Cost-effectiveness of dimethyl fumarate (Tecfidera ) for the treatment of adult patients with relapsing remitting multiple sclerosis The NCPE has issued a recommendation regarding the cost-effectiveness

Information About Medicines for Multiple Sclerosis Information About Medicines for Multiple Sclerosis What is multiple sclerosis? 1 Multiple sclerosis (MS) is a lifelong disease that affects your brain

Multiple Sclerosis: What You Need To Know For Professionals What will I learn today? The Basics: What is MS? Living with MS: A Family Affair We Can Help: The National MS Society What MS Is: MS is thought

Summary & Future perspectives 123 Multiple sclerosis is a chronic disorder of the central nervous system, characterized by inflammation and axonal degeneration. All current therapies modulate the peripheral

National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Chemotherapy The literal meaning of the term chemotherapy is to treat with a chemical agent, but the term generally refers

Supporting MS-Related Disability Claims to Private Insurers: The Physician s Role What Is This Guide? This guide was compiled by the National Multiple Sclerosis Society as an aid to health care professionals

IF YOU ARE RECEIVING (NATALIZUMAB) TREATMENT WITH TYSABRI FOR RELAPSING-REMITTING MS Read the patient information leaflet that accompanies the medicine carefully. 1 This brochure is a supplement to the

The Many Faces of MS Patricia A. Modica, OD, FAAO SUNY College of Optometry Kelly Malloy, OD, FAAO Pennsylvania College of Optometry at Salus University Multiple Sclerosis (MS) Most common acquired disease

Apitope study The study drug (ATX-MS-1467) is a new investigational drug being tested as a potential treatment for relapsing forms of multiple sclerosis (RMS). The term investigational drug means it has

Teriflunomide for treating relapsing remitting multiple Issued: January 2014 last modified: June 2014 guidance.nice.org.uk/ta NICE has accredited the process used by the Centre for Health Technology Evaluation

Treatment guidelines for relapsing MS and the two step approach for disease modifying therapy Klaus Schmierer, PhD FRCP Blizard Institute, Barts and The London School of Medicine & Dentistry Barts Health

Disease modifying drug therapy what you need to know Third Edition Karen Alldus Simon Webster SECTION 2 We hope you find the information in this book helpful. If you would like to speak with someone about

Disclosures New Horizons in Multiple Sclerosis Management Jody Corey-Bloom, MD, PhD University of California, San Diego Principal Investigator on numerous clinical trials for dementia; support from various

Information about medicines for multiple sclerosis Information about medicines for multiple sclerosis What is multiple sclerosis? 1 Multiple sclerosis (MS) is a lifelong disease that affects your brain